Article

Mi-2β-targeted inhibition induces immunotherapy response in melanoma

2020-12-16

Abstract excerpt

<title>Abstract</title> <p>Recent development of some new immune checkpoint inhibitors has been particularly successfully in melanoma, but the majority of melanoma patients exhibit resistance. Understanding and targeting the potential underlying mechanism/targets, especially the tumor-intrinsic modulators to convert resistant melanomas to immunotherapy sensitivity will potentially provide a significant improvemen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b5dc463a-4b08-5249-b1a3-6116f173c803
DOI: 10.21203/rs.3.rs-118153/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mi-2β-targeted inhibition induces immunotherapy response in melanomaDOI 10.21203/rs.3.rs-118153/v1Read

Mi-2β promotes immune evasion in melanoma by activating EZH2 methylationSemantic proximity Read

MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Semantic proximity Read

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanomaSemantic proximity Read

Role of Histone Deacetylases in Drug-Resistant Melanoma: Mechanisms and Therapeutic ImplicationsSemantic proximity Read

IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomasSemantic proximity Read

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibitionSemantic proximity Read

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistanceSemantic proximity Read

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted TherapiesSemantic proximity Read

A Review for Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase InhibitorsSemantic proximity Read

Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targetsSemantic proximity Read

<i>ZNF180</i> modulates tumor intrinsic immunotherapy resistance in melanoma through driving plasticitySemantic proximity Read

YAP1 drives aggressive and therapy resistant state in melanoma through reprogramming the chromatin and regulating immune evasive programsSemantic proximity Read